- Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655
- Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2024 Financial Results
- Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024
- Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024
- Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results
- Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
More ▼
Key statistics
On Wednesday, Nuvalent Inc (NUVL:NSQ) closed at 69.82, -21.89% below its 52-week high of 89.39, set on Mar 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 69.73 |
---|---|
High | 71.00 |
Low | 69.29 |
Bid | 28.44 |
Offer | 80.89 |
Previous close | 69.73 |
Average volume | 348.14k |
---|---|
Shares outstanding | 64.56m |
Free float | 54.52m |
P/E (TTM) | -- |
Market cap | 4.50bn USD |
EPS (TTM) | -2.41 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼